Voices
Estela Rodriguez on FDA Approval of Monthly Subcutaneous Amivantamab for EGFR-Mutant NSCLC
Estela Rodriguez/doctors.umiamihealth.org

Estela Rodriguez on FDA Approval of Monthly Subcutaneous Amivantamab for EGFR-Mutant NSCLC

Estela Rodriguez, Associate Director of Community Outreach- Thoracic Oncology at Sylvester Comprehensive Cancer Center, shared on X:

“FDA Oncology approves today amivantamab once a month subq formulation (plus lazertinib) for EGFR +NSCLC based on Ph2 PALOMA2 trial 80% decrease in Infusion Related reactions convenience for patients w monthly subq after first 4 weekly treatments No change in drug related skin toxicities.”

Estela Rodriguez

Title: Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: the phase 1b PALOMA study

Authors: Anna Minchom, Byoung Chul Cho, Natasha B. Leighl, Melissa L. Johnson, Joshua Sabari, Se-Hoon Lee, Ki Hyeong Lee, Yu Jung Kim, Rachel E. Sanborn, Bert O’Neil, Kamya Sankar, Anna Mitselos, Donna Zemlickis, Carmel Collins, Ali Alhadab, Pamela L. Clemens, Busola Sanusi, Eileen Berkay, Mahadi Baig, Roland E. Knoblauch, Peter Hellemans, Matthew G. Krebs

Read The Full Article

Estela Rodriguez

Other articles about FDA on OncoDaily.

 

Ali Alhadab Anna Minchom Anna Mitselos Bert O’Neil Busola Sanusi Byoung Chul Cho cancer Carmel Collins Donna Zemlickis EGFR Eileen Berkay FDA Joshua Sabari Kamya Sankar Ki Hyeong Lee Mahadi Baig Matthew G. Krebs Melissa L. Johnson Natasha B. Leighl OncoDaily Oncology Pamela L. Clemens Peter Hellemans Rachel E. Sanborn Roland E. Knoblauch Se-Hoon Lee Yu Jung Kim